Adipose stem cells' niche in obesity

脂肪干细胞在肥胖中的作用

• 批准号: 10363226
• 负责人: Niketa A. Patel
• 金额: --
• 依托单位: JAMES A. HALEY VA MEDICAL CENTER
• 依托单位国家: 美国
• 财政年份: 2017
• 资助国家: 美国
• 起止时间: 2017-04-01 至 2025-12-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10363226
• 关键词: Adipocytes; Adipose tissue; Adult; Affect; Afghanistan; Biochemical; Biology; Blood Vessels; Body mass index; COVID-19; COVID-19 pandemic; Cardiovascular Diseases; Caring; Cause of Death; Cells; Centers for Disease Control and Prevention (U.S.); Chronic; Chronic Disease; Clinical; Core Facility; Data; Department of Defense; Development; Diabetes Mellitus; Disease; Endocrine; Evaluation; Expenditure; Fatality rate; Genes; Genetic; Genomic medicine; Glucocorticoid Receptor; Goals; Guidelines; Gulf War; Health; Health Care Costs; Homeostasis; Human; Hyperplasia; Hypertrophy; In Vitro; Inflammation; Inflammatory; Insulin; Insulin Receptor; Insulin Resistance; Iraq; Knowledge; Malignant Neoplasms; Mediating; Medical; Metabolic; Metabolic Diseases; Metabolic Pathway; Metabolic dysfunction; Metabolic stress; Metabolic syndrome; Metabolism; Molecular; Morbid Obesity; Mus; Non-Insulin-Dependent Diabetes Mellitus; Nonsense-Mediated Decay; Obese Mice; Obesity; Overweight; Pathology; Pathway interactions; Pattern; Physiological; Plasmids; Population; Public Health; RNA; Regulator Genes; Reporting; Research; Research Personnel; Risk Factors; Role; Severities; Small Interfering RNA; Thinness; Tissue Differentiation; United States Department of Veterans Affairs; United States National Center for Health Statistics; Untranslated RNA; Veterans; Woman; Work; beneficiary; comorbidity; diet-induced obesity; experience; experimental study; frontier; genetic makeup; growth arrest specific transcript 5; in vitro Model; in vivo; individual patient; insulin signaling; interdisciplinary approach; lipid biosynthesis; military veteran; mortality; mouse model; novel therapeutics; obese patients; obese person; obesity treatment; overexpression; pre-clinical; prevent; receptor; screening; small molecule; small molecule therapeutics; statistics; stem cell biomarkers; stem cell differentiation; stem cell niche; stem cells; tool; transcriptomics

Obesity continues to escalate as a significant public health problem and as the leading preventable cause of death. Stark data from COVID19 pandemic shows obesity is an independent risk factor of severity with 33% mortality rate. Obesity per se is not fatal but is the major health risk factor promoting severe diseases including cardiovascular diseases, type 2 diabetes mellitus, and certain cancers. 42% of adult population in US is obese (CDC NCHS report 2020). Healthcare costs related to obesity account for greater than 10% of total US medical expenditures and has risen to $254 billion per year (1). Alarmingly 78% of the Veteran population is obese, a notably higher percent compared to civilian population(2). Adipose tissue is an important endocrine regulator of energy homeostasis and metabolism. During adipogenesis, the adipose stem cells (ASC) differentiate into adipocytes and replenish the body’s need for new adipocytes. Normal adiposity is exaggerated in obesity and is accompanied by adipocyte hyperplasia and hypertrophy. Previously this lab demonstrated that obesity changes the human adipose stem cells’ niche such that it promotes a microenvironment conducive to developing obesity-associated comorbidities. A significant finding was that the expression of long noncoding RNAs (lncRNAs) differed in the obese ASC compared to lean subjects which contributed to the aberrant metabolic processes, insulin resistance and chronic low-grade inflammation observed in obesity. Using an unbiased transcriptomic screening, this lab identified lncRNA GAS5 as an important regulatory gene that is depleted in human obese adipose tissue, ASC and mature adipocytes compared to lean. Prior research has demonstrated that GAS5 regulates insulin receptor and glucocorticoid receptor mediated pathways. However, the importance and impact of low GAS5 levels on the metabolic pathways in obese adipocytes has not yet been thoroughly investigated. Hence, it is hypothesized that low levels of GAS5 substantially contributes to the manifestation of comorbidities associated with obesity. Towards the overarching goal to determine if GAS5 supports healthy adipocytes, the proposal will evaluate the underlying mechanisms and role of GAS5 in human obese ASC and adipocytes using a multi-disciplinary approach including pre-clinical, physiological, cellular and biochemical experiments. Specific Aim 1: Determine the role of GAS5 in ASC and adipocytes: It is hypothesized that manipulating GAS5 levels will affect the metabolic health of ASC and adipocytes. GAS5 siRNA or over-expression plasmid will be used to evaluate the genetic and metabolic parameters pertaining to adipocyte health and function. Specific Aim 2: Elucidate molecular mechanisms regulated by GAS5 in obese adipocytes: GAS5 levels are low in ASC and adipose tissue in obesity. A small molecule that stabilizes GAS5 has been recently developed. It is hypothesized that stabilizing GAS5 levels could alleviate the metabolic stress and the project will use this compound as a molecular tool to determine the underlying molecular mechanisms with functional readouts. Specific Aim 3: Investigate the impact of GAS5 stabilization in vivo in an obese mouse model: The in vitro data shows that the small molecule targeting GAS5 increases IR levels, restores insulin signaling and regulates GR-target genes. This aim will systematically elucidate the physiological effects of stabilizing GAS5 with the novel therapeutic in a diet-induced obese mouse model. Overall, this project fills significant gaps in knowledge to understand the role of lncRNAs in the metabolic processes affecting adipose tissue in obesity in humans. Identification of GAS5 as a druggable RNA target in a metabolic disease has led to successfully develop a small molecule therapeutic that stabilizes GAS5 (a frontier in genomic medicine) with a high potential of promoting the metabolic health of ASC and adipocytes in obesity. This project will have a considerable impact to prevent or treat metabolic dysfunction associated with obesity, thus impeding the ascent of obesity as the most preventable cause of death.

肥胖作为一个重大的公共卫生问题和可预防的主要原因继续升级。 死亡。来自COVID19大流行的史塔克数据显示，肥胖是严重程度的独立危险因素，33% 死亡率。肥胖本身不是致命的，但它是导致严重疾病的主要健康风险因素，包括 心血管疾病、2型糖尿病和某些癌症。美国42%的成年人肥胖 (CDC NCHS报告2020)。与肥胖相关的医疗费用占美国总支出的10%以上 医疗支出，已增至每年2540亿美元(1)。令人震惊的是，78%的退伍军人 肥胖，与平民人口相比明显更高的百分比(2)。 脂肪组织是能量动态平衡和代谢的重要内分泌调节器。在.期间 脂肪生成，脂肪干细胞(ASC)分化为脂肪细胞，补充身体对 新的脂肪细胞。正常肥胖在肥胖中被夸大，并伴有脂肪细胞增生 和肥大。此前，该实验室证明了肥胖会改变人类脂肪干细胞的生态位。 因此，它促进了有利于发展与肥胖相关的共病的微环境。一个 重要的发现是在肥胖的ASC中，长非编码RNA(LncRNAs)的表达有所不同 与导致异常代谢过程的瘦身受试者相比，胰岛素抵抗和 肥胖症中观察到的慢性低度炎症。使用无偏转录本筛选，本实验室 发现lncRNA Gas5是一个重要的调控基因，在人类肥胖脂肪组织中缺失， ASC和成熟脂肪细胞比较瘦身。先前的研究表明，Gas5调节胰岛素 受体和糖皮质激素受体介导的通路。然而，低Gas5的重要性和影响 肥胖脂肪细胞代谢途径上的水平还没有得到彻底的研究。因此，它是 假设低水平的Gas5在很大程度上促进了共病的表现 与肥胖有关。为了确定Gas5是否支持健康的脂肪细胞， 提案将评估Gas5在人类肥胖的ASC和脂肪细胞中的潜在机制和作用 使用多学科方法，包括临床前、生理、细胞和生化实验。 特定目标1：确定Gas5在ASC和脂肪细胞中的作用：假设操纵 Gas5水平会影响ASC和脂肪细胞的代谢健康。Gas5 siRNA或过表达载体 将用于评估与脂肪细胞健康和功能有关的遗传和代谢参数。 特定目标2：阐明Gas5调节肥胖脂肪细胞的分子机制：Gas5水平 肥胖者ASC和脂肪组织含量较低。一种稳定Gas5的小分子最近被开发出来。 据推测，稳定Gas5水平可以缓解代谢压力，该项目将使用这一点 化合物作为一种分子工具，通过功能读数来确定潜在的分子机制。 具体目标3：研究Gas5在体内对肥胖小鼠模型的影响：体外 数据显示，靶向Gas5的小分子增加IR水平，恢复胰岛素信号和 调节GR靶基因。这一目标将系统地阐明稳定Gas5的生理效应 在饮食诱导的肥胖小鼠模型中使用这种新的治疗方法。 总体而言，这个项目填补了在理解lncRNAs在 人类肥胖时影响脂肪组织的代谢过程。Gas5作为一种可药物的鉴定 新陈代谢疾病中的RNA靶点导致成功开发出一种稳定的小分子疗法 Gas5(基因组医学的前沿)，具有促进ASC和ASC代谢健康的高潜力 肥胖中的脂肪细胞。该项目将对预防或治疗代谢功能障碍产生相当大的影响 与肥胖有关，从而阻碍肥胖症上升为最可预防的死亡原因。